Evommune Q2 2026: $288M Runway Through 2028, Key Pipeline Readouts Looming
EVMN sits 25% above its 52-week low of $10.47.
Summary
Evommune's Q2 2026 filing shows a strong cash position funding operations through 2028, with pivotal Phase 2b atopic dermatitis data for EVO756 expected in September 2026 — a key event after the recent CSU trial failure.
Key Events · Earnings and Guidance · EVMN
-
Q2 2026 Financials
A net loss of $32.2M was recorded on no revenue, while R&D spending climbed to $26.4M, driven by the EVO756 trials. Cash, equivalents, and investments stand at $288.0M, which is expected to fund operations through 2028.
-
Pipeline Update & Upcoming Catalysts
Phase 2b atopic dermatitis data for EVO756 is expected in September 2026; a Phase 2b migraine trial was initiated in July 2026, with data anticipated in 2027. Additionally, EVO301 Phase 2b is planned for mid-2027.
-
10b5-1 Plan Termination
On May 28, 2026, Chief Medical Officer Eugene Bauer terminated a Rule 10b5-1 trading plan that had covered up to 108,120 shares.
Analysis · EVMN · Life Sciences
A $32.2M net loss was posted for Q2 2026, yet the $288M in cash and investments is expected to fund operations through 2028. The spotlight now falls on EVO756, which is advancing in atopic dermatitis and migraine after the CSU setback; Phase 2b AD data due in September 2026 could redefine the program's value. Separately, the Chief Medical Officer terminated a 10b5-1 trading plan in May — a governance detail worth noting alongside the pipeline updates.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1912 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $13.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $481.9M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.